NEKTAR THERAPEUTICS - 10-Q Filing
Nektar Therapeutics reports Q3 financial results including restructuring costs and ongoing R&D for TNFR2 and Rezpegaldesleukin programs.
Tickers: $NKTR
More Regulatory news
- Nova Minerals Corp - 8-K Filing
- Vertiv Holdings Co - 8-K Filing
- Rezolute, Inc. - 8-K Filing
- REGIONAL HEALTH PROPERTIES, INC - 10-Q Filing
- BLUE BIOFUELS, INC. - 10-Q Filing
- First Choice Healthcare Solutions, Inc. - 10-Q Filing
- OpenWorld, Inc. - 10-Q Filing
- NEKTAR THERAPEUTICS - 8-K Filing
- Weatherford International Corp - 8-K Filing
- iRhythm Holdings, Inc. - 8-K Filing